In a complex regulatory environment, post-market surveillance is a continuous process that demands precision, adaptability ...
Gilead licences Sprint Bioscience’s pre-clinical TREX1 inhibitor programme, gaining a novel immuno-oncology asset targeting ...
The Vendor-Neutral MSP and Real-World Data: Optimizing Workforce Deployment for Post-Market Surveill
In a complex regulatory environment, post-market surveillance is a continuous process that demands precision, adaptability and scale. As life sciences organizations increasingly rely on real-world ...
The Food for the Brain Foundation’s Cognitive Function Test will now be used to assess blood biomarkers being developed in the ‘READ OUT’ trial, a UK-based research project. The project, headed by ...
Global Dental Equipment Market OverviewThe global dental equipment market is projected to grow at a rate of 5–6% over the next five years. Factors such as an aging population, particularly in ...
Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted ...
Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the ...
Vivan Therapeutics and the MRC Laboratory of Medical Sciences Announces a Pioneering Partnership to Explore How Specific Cancer Mutations, Diabetes & Diet Influence Drug Response London, UK [November ...
Report OverviewThe global medical billing software market is on track to grow at a robust pace, with expectations of achieving a CAGR of approximately 10% throughout the forecast period. This growth ...
Global Healthcare IT Market OverviewThe global healthcare IT market is positioned for rapid expansion, projecting a strong CAGR of 16% between 2025 and 2030. The sector’s growth is largely driven by ...
IntroductionThe global herbal medicinal products market is poised for steady growth in the coming years, supported by a substantial rise in consumer interest in natural, plant-based treatments and ...
Modus Therapeutics Holding AB (“Modus Therapeutics”) hereby publishes an interim report for the third quarter of 2025. The report is available on the company’s website ( and as an attachment to this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback